SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

Search

Orion Oyj (Class B)

Затворен

66.55 -0.15

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

66.55

Максимум

66.85

Ключови измерители

By Trading Economics

Приходи

-12M

61M

Продажби

-80M

355M

P/E

Средно за сектора

25.565

39.564

EPS

0.44

Дивидентна доходност

2.57

Марж на печалбата

17.287

Служители

3,943

EBITDA

202M

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.57%

2.40%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

3.4B

8.9B

Предишно отваряне

66.7

Предишно затваряне

66.55

Orion Oyj (Class B) Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.07.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

FCC Approves U.S. Cellular Sale to T-Mobile

11.07.2025 г., 17:28 ч. UTC

Значими двигатели на пазара

SharpLink Gaming Gains on Ethereum Purchase

11.07.2025 г., 16:57 ч. UTC

Печалби

BASF Cuts Outlook on Global Economy Uncertainty

12.07.2025 г., 17:01 ч. UTC

Печалби

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12.07.2025 г., 14:53 ч. UTC

Печалби

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12.07.2025 г., 02:24 ч. UTC

Придобивния, сливания и поглъщания

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12.07.2025 г., 02:05 ч. UTC

Придобивния, сливания и поглъщания

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12.07.2025 г., 02:05 ч. UTC

Придобивния, сливания и поглъщания

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12.07.2025 г., 02:05 ч. UTC

Придобивния, сливания и поглъщания

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11.07.2025 г., 19:46 ч. UTC

Придобивния, сливания и поглъщания

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11.07.2025 г., 19:45 ч. UTC

Пазарно говорене

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11.07.2025 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11.07.2025 г., 18:18 ч. UTC

Пазарно говорене

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11.07.2025 г., 17:35 ч. UTC

Пазарно говорене

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11.07.2025 г., 17:26 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11.07.2025 г., 16:53 ч. UTC

Пазарно говорене

Crude Futures Add to Early Gains -- Market Talk

11.07.2025 г., 16:42 ч. UTC

Печалби

BASF Cuts Outlook on Global Economic Uncertainty

11.07.2025 г., 16:08 ч. UTC

Пазарно говорене

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11.07.2025 г., 16:05 ч. UTC

Печалби

BASF Will Publish Half-Year Results on July 30

11.07.2025 г., 16:04 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.07.2025 г., 16:04 ч. UTC

Пазарно говорене

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11.07.2025 г., 16:03 ч. UTC

Печалби

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11.07.2025 г., 16:02 ч. UTC

Печалби

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11.07.2025 г., 16:01 ч. UTC

Печалби

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11.07.2025 г., 16:00 ч. UTC

Печалби

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11.07.2025 г., 15:59 ч. UTC

Печалби

BASF Cuts 2025 Earnings View

11.07.2025 г., 15:58 ч. UTC

Печалби

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11.07.2025 г., 15:57 ч. UTC

Печалби

BASF 2Q EBIT Before Special Items EUR810M

11.07.2025 г., 15:54 ч. UTC

Печалби

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

Сравнение с други в отрасъла

Ценова промяна

Orion Oyj (Class B) Прогноза

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.